India, April 8 -- Novo Nordisk recently presented the full results from theSOULcardiovascular outcomes trial, demonstrating that oral semaglutide significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

These new data from the phase 3b trial were featured during a late-breaking clinical trial session at theAmerican College of Cardiology's (ACC) Annual Scientific Session and Expoin Chicago, US and simultaneously published inNew England Journal of Medicine.

TheSOULtrial achieved its primary endpoint, demonstrating a 14% reduction in risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and CVD and/o...